

Session Title: #36: Current Challenges for Cellular Therapies

Session Type: Education Session

Date: Friday, June 4

Location: S504

Time: 3:30 PM - 4:45 PM

- When should immunablative therapies be considered in the treatment of pediatric cancer?

John M. Cunningham, MBBS

- Adoptive cellular therapies utilizing gene modified lymphocytes

Laurence Cooper, MD, PhD

- The role of NK cells in transplant and the non-transplant scenario

Wing H. Leung, MD, PhD

Session Title: #35: Curable and Highly Treatable Leukemias: How Do I Optimize Outcome?

Session Type: Education Session

Date: Saturday, June 5

Location: E354a

Time: 8:00 AM - 9:15 AM

- Update on acute promyelocytic leukemia

Bayard L. Powell, MD

- Monitoring recommendations. What defines resistance?

Giuseppe Saglio, MD

- Therapy for CML. What is the best TKI? When? And beyond?

Moshe Talpaz, MD

Session Title: #205: Leukemia, Myelodysplasia, and Transplantation

Session Type: General Poster Session

Date: Saturday, June 5

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

11B #6534-Thymic renewal and antileukemic effect in adults after haploidentical transplantation and suicide gene therapy.

Claudio Bordignon

11F #6535-First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol.

Damiano Rondelli

11G #6536-EPOCH-FR: A novel salvage regimen for patients with lymphoid malignancies being considered for reduced-intensity allogeneic hematopoietic stem cell transplantation.

Rachel B Salit

11H #6537-A prospective feasibility study of clofarabine (CLO) cyto-reduction prior to allogeneic stem cell transplant (HCT) conditioning for refractory leukemia and MDS.

Frederick Lundry Locke

12A #6538-90y-ibrutinomab tiuxetan followed by reduced-intensity conditioning (RIC) and allogeneic stem-cell transplantation (SCT) in patients with high-risk relapsed, refractory, or transformed follicular lymphoma (FL).

Karim Abou-Nassar

12B #6539-Treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapsing after allogeneic hematopoietic cell transplantation (HCT).

Alexandre Chiatton

12F #6540-Single-nucleotide polymorphism analysis of candidate genes in chronic GVHD.

William B. Clark

12G #6541-Pharmacokinetics and assessment of renal toxicity of a clofarabine (Clo), melphalan (Mel), and alemtuzumab (Alm) conditioning regimen.

Koen van Besien, MD

12H #6542-Is there a relationship between glucocorticoid (GC) dose and performance on functional outcome measures?

Janet S. Scheetz

13A #6543-Phase I dose-escalation trial of high-dose melphalan (M) with palifermin (P) for cytoprotection followed by autologous stem cell transplantation (ASCT) for myeloma (MM) patients with normal renal function (NRF).

Muneer Hyder Abidi

13B #6544-CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: Potential predictor of early engraftment.

Kumar Prabhash

13C #6545-Results of new cases of APL treatment by arsenic trioxide and long-term follow-up: Is it time for using arsenic trioxide in first-line treatment?

Ardeshir Ghavamzadeh

13D #6546-Use of deep whole transcriptome sequencing in Philadelphia-positive acute lymphoblastic leukemia (ALL) to identify novel mutated genes and aberrant gene expression and alternative splicing profiles associated with disease progression.

Ilaria Iacobucci

13E #6547-The relationship of cigarette smoking to invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients undergoing induction chemotherapy (IC).

Mary George Mansour

13F #6548-Dynamic of morphologic and molecular remission in patients (pts) with APL treated with frontline ATRA and arsenic trioxide (ATO).

Mohamad Ayoubi

13G #6549-Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies.

Andrea Dean

13H #6550-Correlation of *RASGRP1/APTX* ratio with clinical response and survival in AML patients treated with tipifarnib-bortezomib combination.

Giovanni Martinelli

14A #6551-Analysis of survival of older patients with frontline AML treated with clofarabine with or without low-dose cytarabine or intermediate-dose cytarabine: A matched cohort comparison.

Stefan Faderl

14B #6552-Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML).

Gautam Borthakur

14C #6553-Association of lymphocytosis following treatment with dasatinib with response and outcome.

Charles Alan Schiffer

14D #6554-Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients.

Simona Soverini

14E #6555-Decitabine therapy in patients with AML or MDS and chromosome 5, 7, or 8 abnormalities.

Sanjay R. Mohan

14F #6556-Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd.

Timothy P. Hughes

14G #6557-Long-term outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML.

David Rizzieri

14H #6558-A clinico-genomic model of performance status in acute myeloid leukemia.

Arati Rao

15A #6559-Obesity, a risk factor for acute myeloid leukemia? Roswell Park Cancer Institute weighs in on the obesity debate.

Hun Ju Lee

15B #6560-Patient and disease characteristics of women with acute myelogenous leukemia (AML) and a history of breast cancer (BC).

Rana R Yehia

15C #6561-Hypocellular acute myeloid leukemia: Better or worse prognosis.

Aref Al-Kali

15D #6562-The role of FLT3 in sole trisomy 8 acute myeloid leukemia.

Anne Marie W. Block

15E #6563-The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ALL.

Sung-Nam Lim

15F #6564-Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS).

David A Macdonald

15G #6565-Survival outcomes after initial infused therapy for elderly chronic lymphocytic leukemia (CLL) patients.

Mark Danese

15H #6566-Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Yiming Chen

16A #6567-BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

Dong-Wook Kim

16B #6568-Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies.

Jeffrey Howard Lipton

16C #6569-Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.

Giuseppe Saglio, MD

16D #6570-Race and overall survival in acute myeloid leukemia.

Jason M. Bierenbaum

16E #6571-Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine.

Amber Fullmer

16F #6572-CPX-351 IN AML after failed induction with cytarabine and daunorubicin.

Jeffrey E. Lancet, MD

16G #6573-Incidence of unconventional infections (UC) in patients with acute myelogenous leukemia (AML) treated with clofarabine (CLO)-containing induction therapy.

Randall W Knoebel, PharmD

16H #6574-Activity of azacitidine in chronic myelomonocytic leukemia.

Rubens Barros Costa

17A #6575-BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.

April H. Teitelbaum

17B #6576-Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN- γ) treatment.

Jack D. Burton

17C #6577-Central nervous system disease and acute myeloid leukemia or chronic myeloid leukemia: Cytogenetic profile.

Ferial Shihadeh

17D #6578-A phase III randomized, double-blind, placebo controlled trial of North American (NA) ginseng (*Panax quinquefolium*) Extract (CVT-E002) in patients with chronic lymphocytic leukemia: Effect on respiratory infection and antibiotic use.

Kevin P. High

17E #6579-Epidemiology, risk factors, and outcomes of invasive fungal infection in adults with acute myelogenous leukemia undergoing intensive induction chemotherapy.

Kit Lu

17F #6580-Family history (FH) of women with breast cancer (BC) and acute myelogenous leukemia (AML).

Kim A Reiss

17G #6581-Serum interleukin-6, cardiovascular disease, and mortality in chronic lymphocytic leukemia.

David E Dawe

17H #6582-Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine.

Mikkael A. Sekeres

18A #6583-Lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia: Report of an ongoing study.

Danelle Frances James

18B #6584-Four routinely recorded parameters define four distinct prognostic groups in AML.

Juergen R Novotny

18C #6585-United States (US) practices for chronic myelogenous leukemia (CML) management compared to other countries: A worldwide observational registry.

Robert C. Hermann

18D #6586-Effect of the presence of P-glycoprotein (MDR1) on the ability of AML patients to achieve complete remission: Results of a meta-analysis of the literature.

Jean Pierre Marie

18E #6587-Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older.

Martha Lucia Arellano

18F #6588-Early intensification of imatinib treatment based on precise definition of accelerated phase in patients with chronic myeloid leukemia: Population-based analysis.

Kajetana Foryciarz

18G #6589-High-dose of daunorubicin as induction treatment for adults with newly diagnosed Philadelphia-negative acute lymphoblastic leukemia.

Sang Min Lee

18H #6590-Prevalence of familial malignancy in a prospectively screened cohort of patients with leukemia.

Aakanksha Prasad

19A #6591-Detection of combinations of cytogenetic abnormalities in chronic lymphocytic leukemia (CLL) by fluorescent in situ hybridization (FISH) probes.

Michael Thomas Schweizer

19B #6592-Molecular characterization of normal karyotype acute myeloid leukemia in Κorean patients.

Yunsuk Choi

19C #6593-Reactivation of latent viral hepatitis infection in patients of chronic myeloid leukemia treated with imatinib mesylate: Experience from a tertiary cancer center in India.

Vikas Ostwal

19D #6594-Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib.

Nikhil Ghadyalpatil

19E #6595-Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia patients: An Indian experience.

Ritwik Pandey

19F #6596-Meta-analysis of cord blood transplantations for indication of leukemia from private umbilical cord blood banks from 1993-2009.

Nina Gottschalk

19G #6597-Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs).

Sameh Gaballa

19H #6598-Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.

Pierre Fenaux

20A #6599-JAK2 V617F mutation positives in the general population.

Stig E. Bojesen

20B #6600-Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes (MDS).

Edward Kim, MD, MBA

20C #6601-Hematologic outcomes of MDS treatment with hypomethylating agents in community practice.

Rodolfo Bordoni

20D #6602-Increased of overall survival (OS) and malignancies (K) during tyrosine kinase inhibitors (TKI) in a real life cohort of patients (pts) with a chronic myeloid leukemia (CML).

Marie-Pierre Gourin

20E #6603-Eltrombopag effect on the engraftment efficiency of human hematopoietic stem cells in a NOD/SCID xenotransplant model.

Yuhchyan Chen, MD, PhD

20F #6604-Nonsteroidal anti-inflammatory drugs (NSAIDs) or EP4 receptor antagonism enhances hematopoietic stem and progenitor cell (HSPC) mobilization and facilitates faster hematopoietic recovery after myeloablation.

Jonathan Hoggatt

20G #6605-Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS).

Naveen Pemmaraju

20H #6606-Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes.

Ghulam J. Mufti

21A #6607-Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS).

Amanda F. Cashen

21B #6608-Identification of genes with different methylation profiles between RAEB and RCMD in myelodysplastic syndrome.

Suee Lee

21C #6609-Effect of phosphoinositide-phospholipase c beta1 monoallelic deletion in low-risk MDS patients treated with darbepoetin.

Pietro Spadaro

21D #6610-In vitro activation of CMV-specific T-cell response using CyaA toxoids delivering peptide antigenic epitopes derived from pp65 protein.

Jiri Jelinek

21E #6611-Myelodysplastic syndrome (MDS) patients at a VA medical center: Comorbidity and survival.

Katherine Kim

21F #6612-A prospective multicenter observational study for decitabine treatment in Κorean patients with myelodysplastic syndrome.

Je-Hwan Lee

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #11: Allogeneic Transplantation Advances and Controversies

Session Type: Education Session

Date: Sunday, June 6

Location: E354b

Time: 8:00 AM - 9:15 AM

- Advances in Alternative Donor Transplant
Koen van Besien, MD
- Reduced intensity, myeloablative and transplant lite. What's in a name?
Parameswaran Hari, MD, MRCP, MS
- Transplant for Acute Myeloid Leukemia: Who should be transplanted in CR1?
Marcos J.G. De Lima, MD

Session Title: #84: Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Session Type: Education Session

Date: Sunday, June 6

Location: S504

Time: 8:00 AM - 9:15 AM

- New insights into the biological basis of ALL
Charles Grenfell Mullighan, MBBS, MSc, MD
- Treatment options for high-risk pediatric and adolescent ALL
Ching-Hon Pui, MD
- Converging approaches to treating childhood, adolescent and young adult ALL
Stephen Hunger, MD

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

- Plenary Session including Science of Oncology Award and Lecture

Frank McCormick, PhD, FRS

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion

Elizabeth A. Eisenhauer, MD

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

Elisabeth A. Quoix

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

Yung-Jue Bang

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #74: Myelodysplastic Syndromes and Elderly Acute Myeloid Leukemia

Session Type: Education Session

Date: Sunday, June 6

Location: E354a

Time: 4:45 PM - 6:00 PM

- Prognostic models in MDS

Guillermo Garcia-Manero, MD

- Beyond supportive care in MDS- growth factors -epigenetic therapies, immunomodulators and novel chemotherapeutic agents.

David Steensma, MD

- Acute Leukemia in the elderly . Who should be treated and how.

Farhad Ravandi Kashani, MD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

- Discussion: Cancer Prevention/Epidemiology

Scott Michael Lippman, MD

Session Title: #87: Personalizing Therapeutic Approaches to Chronic Lymphocytic Leukemia

Session Type: Education Session

Date: Monday, June 7

Location: E354a

Time: 8:00 AM - 9:15 AM

- Prognostic markers in CLL, do they matter?

Sami N. Malek, MD

- CLL in the elderly. How should it be treated?

Clive Zent, MD

- Evolving therapies for CLL

Susan Mary O'Brien, MD

Session Title: #157: Leukemia, Myelodysplasia, and Transplantation

Session Type: Oral Abstract Session

Date: Monday, June 7

Location: E354b

Time: 9:30 AM - 12:30 PM

- Leukemia, Myelodysplasia, and Transplantation

William G. Blum, MD

- Leukemia, Myelodysplasia, and Transplantation

Jessica K. Altman, MD

- #LBA6500-Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.

Hagop Kantarjian

- #6501-Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.

Richard A. Larson

- #6502-Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).

Jorge E. Cortes

- Discussion: Chronic Phase CML- Beyond Imatinib?

Michael J. Mauro, MD

- #6503-Time-dependent decision analysis: Stable disease in azacitidine (AZA) treated patients (pts) with higher-risk MDS.

Steven Gore

- #6504-A randomized study of two dose levels of intravenous (IV) clofarabine (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS).

Elias Jabbour

- #6505-Improvement of leukemia-free survival (LFS) and reduction of relapse incidence by allogeneic stem cell transplantation (SCT) in elderly patients (pts) with AML irrespective of the FLT3-ITD and nrm status except nrm+/flt3(ITD)-.

Dietger Niederwieser

- Discussion: High risk MDS and AML in the elderly. Are we making progress?

Jeffrey E. Lancet, MD

- #6506-Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).

Deborah A. Thomas

- #6507-Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).

Susan Mary O'Brien, MD

- #6508-A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia.

Xavier Badoux

Session Title: #98: The Biology of Leukemia and Myeloproliferative Disorders: Implications for Treatment

Session Type: Education Session

Date: Monday, June 7

Location: E354b

Time: 1:15 PM - 2:30 PM

- JAK 2 and related mutations in myeloid neoplasms. Biology and therapeutic implications

Catriona Jamieson, MD, PhD

- Epigenetic and other rational therapeutic approaches in MPD.

Olatoyosi Odenike, MD

- Micro RNA in AML and CLL. What does it mean?

Guido Marcucci, MD

Session Title: #184: Leukemia, Myelodysplasia, and Transplantation

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: E450a

Time: 2:00 PM - 6:00 PM

- Leukemia, Myelodysplasia, and Transplantation

Rami S. Komrokji, MD

- Leukemia, Myelodysplasia, and Transplantation

Lucy A. Godley, MD, PhD

1 #6509-Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.

Carlo Gambacorti-Passerini

2 #6510-Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib.

Francis J. Giles

3 #6511-Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.

Moshe Talpaz, MD

4 #6512-Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.

Neil P. Shah

5 #6513-Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib.

Susan Branford

6 #6514-Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).

Hanna Jean Houry

- Discussion: Optimizing TKI therapy in advanced CML (Back up speaker is Meir Wetzler at Roswell Park)

Mier Wetzler, MD, FACP

7 #6515-Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years.

Gianantonio Rosti

8 #6516-Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

Andreas Hochhaus

9 #6517-Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV.

Rudiger Hehlmann

10 #6518-Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients.

Amit Roy

11 #6519-Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).

Sameer A Parikh

12 #6520^ -Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL).

William Wierda

13 #6521-Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS).

Apostolia Tsimberidou

14 #6522-Phase II trial of daily, oral green tea extract in patients with asymptomatic, Rai stage 0-II chronic lymphocytic leukemia (CLL).

Tait D. Shanafelt, MD

15 #6523-Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia.

Robert J. Kreitman

- Discussion: Advances in the therapy of chronic lymphoid leukemias

John C. Byrd, MD

16 #6524-Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL).

Carlos Enrique Vigil, MD

17 #6525-Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.

Robert K. Stuart

18 #6526-Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.

Gail J. Roboz

19 #6527-Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR).

Farhad Ravandi Kashani, MD

20 #6528-A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents.

Guillermo Garcia-Manero, MD

- Discussion: Novel therapeutic strategies in MDS and AML

Harry Paul Erba, MD, PhD

21 #6529-Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or older) with acute myeloid leukemia (AML) treated with intensive chemotherapy (IC).

Tapan M. Kadia

22 #6530-Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients.

Claude Gardin

23 #6531-Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies.

Maria R. Baer

24 #6532-Treatment of acute myeloid leukemia (AML) in first remission (CR1) with unrelated donor (UD) allogeneic hematopoietic cell transplantation (HCT).

Qaiser Bashir

- Discussion: Can management of high risk AML be optimized? (Back up speaker Bob Loewenberg Rotterdam, Netherlands)

Jane Liesveld, MD

Session Title: #6: Acute Leukemia: Integration of Novel Diagnostic and Therapeutic Measures

Session Type: Education Session

Date: Monday, June 7

Location: E354a

Time: 3:00 PM - 4:15 PM

- Molecular/cytogenetic prognostication in AML and its impact on treatment.

Richard F. Schlenk, MD

- Upfront and Salvage therapy in AML. What's new?

Ivana Gojo, MD

- An update on treatment of adult ALL.

Anjali S. Advani, MD

Session Title: #251: Leukemia, Myelodysplasia, and Transplantation

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: E354a

Time: 5:00 PM - 6:00 PM

- Leukemia, Myelodysplasia, and Transplantation

Lucy A. Godley, MD, PhD

- Leukemia, Myelodysplasia, and Transplantation

Rami S. Komrokji, MD

1 #6509-Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.

Carlo Gambacorti-Passerini

2 #6510-Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib.

Francis J. Giles

3 #6511-Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.

Moshe Talpaz, MD

4 #6512-Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.

Neil P. Shah

5 #6513-Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib.

Susan Branford

6 #6514-Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).

Hanna Jean Houry

- Discussion: Optimizing TKI therapy in advanced CML (Back up speaker is Meir Wetzler at Roswell Park)

Mier Wetzler, MD, FACP

7 #6515-Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years.

Gianantonio Rosti

8 #6516-Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

Andreas Hochhaus

9 #6517-Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV.

Rudiger Hehlmann

10 #6518-Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients.

Amit Roy

11 #6519-Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).

Sameer A Parikh

12 #6520^ -Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL).

William Wierda

13 #6521-Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS).

Apostolia Tsimberidou

14 #6522-Phase II trial of daily, oral green tea extract in patients with asymptomatic, Rai stage 0-II chronic lymphocytic leukemia (CLL).

Tait D. Shanafelt, MD

15 #6523-Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia.

Robert J. Kreitman

- Discussion: Advances in the therapy of chronic lymphoid leukemias

John C. Byrd, MD

16 #6524-Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL).

Carlos Enrique Vigil, MD

17 #6525-Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.

Robert K. Stuart

18 #6526-Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.

Gail J. Roboz

19 #6527-Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR).

Farhad Ravandi Kashani, MD

20 #6528-A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents.

Guillermo Garcia-Manero, MD

- Discussion: Novel therapeutic strategies in MDS and AML

Harry Paul Erba, MD, PhD

21 #6529-Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or older) with acute myeloid leukemia (AML) treated with intensive chemotherapy (IC).

Tapan M. Kadia

22 #6530-Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients.

Claude Gardin

23 #6531-Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies.

Maria R. Baer

24 #6532-Treatment of acute myeloid leukemia (AML) in first remission (CR1) with unrelated donor (UD) allogeneic hematopoietic cell transplantation (HCT).

Qaiser Bashir

- Discussion: Can management of high risk AML be optimized? (Back up speaker Bob Loewenberg Rotterdam, Netherlands)

Jane Liesveld, MD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III
Kathy Miller, MD
- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy
Kathy Miller, MD
- Discussion: Lung Cancer - Metastatic
Charles M. Rudin, MD, PhD
- Discussion: Sarcoma
Gary K. Schwartz, MD
- Discussion: Gastrointestinal (Noncolorectal) Cancer
C. D. Blanke, MD
- Discussion: Head and Neck Cancer
Everett E. Vokes, MD